Valencia, Spain and New York, January 28, 2025 – Quibim, a healthtech firm centered on the usage of imaging biomarkers for precision drugs, introduced right this moment the shut of its $50 million Collection A financing.
The corporate mentioned it has skilled progress within the variety of sufferers analyzed by its merchandise over the previous 12 months. Pushed by a number of regulatory approvals and world business partnerships, affected person evaluation surged by 168% quarter-on-quarter. The financing was led by Asabys (via its fund Sabadell Asabys II) and Buenavista Fairness Companions (via the BHG I fund, created in partnership with Columbus Enterprise Companions), and joined by UI Investissements, and GoHub Ventures as new traders. It was additionally joined by present traders, Amadeus Capital Companions, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund’s early progress fund), Tony Fadell’s Construct Collective, and particular person investor Dr. Jonathan Milner, founding father of Abcam plc.
Quibim is devoted to the formidable mission of unlocking a whole, non-invasive understanding of each tissue level within the human physique, at any second in time. To attain this, the corporate develops foundational AI fashions utilized to imaging that extract actionable insights from MRI, CT, and PET scans. These insights allow exact characterization of phenotypes and prediction of outcomes in areas reminiscent of oncology, immunology, neurology and metabolic issues.
That is the pathway towards reaching human digital twins, dynamic fashions that not solely replicate and permit well being monitoring but in addition improve affected person stratification, enhance the success charges of drug growth packages, and allow therapy testing earlier than software. Immediately, the corporate is constructing digital twins on the organ and lesion stage, exemplified by options like QP-Mind, QP-Prostate, and QP-Liver.
Nevertheless, as the quantity of whole-body scans and associated imaging knowledge continues to develop, within the coming years Quibim fashions will analyze your complete physique. The imaginative and prescient of the corporate is to catalyze this revolutionary step in healthcare by merging imaging applied sciences, computing, and AI.
With over 170 installations worldwide, together with prestigious establishments like Mass Common Brigham and Stanford, and regulatory clearances throughout the US, EU, UK, and different areas, Quibim’s know-how bridges the hole between analysis, scientific follow, and drug growth. Final 12 months, Philips introduced a world partnership with Quibim to combine its AI fashions into MR scanners, whereas the corporate additionally secured strategic alliances with main biopharma giants reminiscent of Merck KGaA and Novartis.
“Quibim’s mission is to show imaging right into a catalyst for precision well being, and we’re deeply grateful to each our new and present traders for his or her assist,” mentioned Dr. Ángel Alberich-Bayarri, CEO and co-founder of Quibim. “Our world enlargement into the U.S. is a essential milestone as we work with pharmaceutical leaders and healthcare suppliers to unlock the ability of imaging to revolutionize diagnostics and enhance affected person outcomes.”
Quibim’s product portfolio contains:
- QP-Prostate: the corporate’s flagship product is designed to reinforce prostate most cancers detection via an industry-leading AI-powered lesion detection*. CE, UKCA marked and 510(ok) cleared.
- QP-Mind: AI-based early-stage neurological illness quantification software program for quantification of early mind atrophy and lesions. CE, UKCA marked and 510(ok) cleared.
- QP-Liver: automated AI software for MR analysis of diffuse liver ailments via correct quantification of tissue fats and iron ranges. CE and UKCA marked.
- QP-Insights: A platform to handle, retailer and analyze multi-omics knowledge in scientific trials and real-world knowledge research. QP-Insights is being utilized by world biopharmaceutical firms, educational medical facilities and analysis consortiums, together with the European Most cancers Imaging Initiative to assist Europe’s Beating Most cancers Plan. QP-Insights is the platform managing the biggest imaging datasets on the earth, accounting for greater than 100 million medical photos.
With the collection A financing, Quibim is establishing a robust U.S. presence, constructing on its success in Europe, via strategic collaborations with hospitals and pharmaceutical firms. By implementing its strategic plan and, via its suite of options already cleared by FDA, the corporate will assist healthcare suppliers and scientific researchers to course of an unprecedented quantity of information from medical scans. Moreover, Quibim’s AI-powered imaging options will empower pharmaceutical firms by enhancing scientific trials and accelerating drug growth with exact, actionable insights derived from imaging biomarkers.
“Asabys is thrilled to assist Quibim in remodeling the imaging diagnostics house,” mentioned Guillem Masferrer, Companion at Asabys Companions. “Their capability to mix AI with imaging biomarker discovery addresses essential unmet wants in oncology, neurology, and past. We’re assured that Quibim’s progressive options may have a profound impression on world healthcare.”
“Quibim’s know-how exemplifies the following wave of precision drugs,” mentioned José Mesa, Companion at Columbus and Buenavista’s consultant on the Board. “Their spectacular observe document with world pharmaceutical partnerships, together with partnerships with firms reminiscent of Merck KGaA and Philips, exemplify Quibim’s function in remodeling imaging knowledge into precious predictions for scientific trials and therapy planning. We anticipate that as Quibim develops its pipeline of companion diagnostic instruments, we are going to see large momentum for its know-how and merchandise.”
“The foundational analysis carried out by Quibim’s group has not solely knowledgeable {industry} requirements, but in addition led to the corporate pioneering an strategy to combining radiomics and deep studying that’s now a normal of its personal.” mentioned Pierre Socha, Companion at Amadeus Capital Companions. “This platform strategy was novel on the time of our first funding and proved to be the suitable technique for speedy scale-up.”
“Excited that Quibim’s AI enabled insights from MRI, CT and PET scans are coming to the US! Their FDA authorised precision evaluation is already being utilized by docs to detect early indicators of ailments like most cancers and assist measure therapy response. Quibim has actually superior precision drugs all over the world!” mentioned Tony Fadell Construct Collective Principal and Nest Founder.
